Silver Book Fact

TAVR v. SAVR in Intermediate-Risk SAS Patients

At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical aortic valve replacement (SAVR)), disabling stroke rates of 2.3% (compared to 5.9% for SAVR), and rehospitalization rates of 11.4% (compared to 15.1% for SAVR).

Thourani V, Kodali S, Makkar R, et al. Transcatheter Aortic Valve Replacement Versus Surgical Valve Replacement in Intermediate-Risk Patients: A propensity score analysis. Lancet. 2016; 387(10034): 2218-25. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30073-3/references

Reference

Title
Transcatheter Aortic Valve Replacement Versus Surgical Valve Replacement in Intermediate-Risk Patients: A propensity score analysis
Publication
Lancet
Publication Date
2016
Authors
Thourani V, Kodali S, Makkar R, et al
Volume & Issue
Volume 387, Issue 10034
Pages
2218-25
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…  
  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • TAVR Procedures 2011 – 2015
    From approval in 2011 through 2015, >54,000 transcatheter aortic valve replacements (TAVRs) were performed in 418 centers in 48 states.  
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states
     
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…